SCHEMBL4417405

SCHEMBL4417405

COC(=O)c1cc2c(-c3ccc(F)cc3)c(-c3ccncc3)c(-c3ccc(F)cc3)nc2o1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 13/20 0.47
MAPK13 O15264 4/20 0.47
MAPK12 P53778 4/20 0.47
MAPK11 Q15759 4/20 0.47
GCGR P47871 2/20 0.47
ALOX5 P09917 1/20 0.47
LMNA P02545 1/20 0.43
HTR3A P46098 1/20 0.41
ADORA2A P29274 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
SLC6A2 P23975 1/20 0.39
HTR2C P28335 1/20 0.39
ADORA1 P30542 1/20 0.39
SRC P12931 1/20 0.39
BRAF P15056 1/20 0.39
KDR P35968 1/20 0.39
MAPK9 P45984 1/20 0.39
CSNK1D P48730 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4411014 0.86 MAPK14 (0.44) MAPK14MAPK13MAPK12MAPK11ALOX5
SCHEMBL4413047 0.85 MAPK14 (0.43) MAPK14SRCBRAFKDRMAPK9
SCHEMBL4415039 0.82 NAMPT (0.43) MAPK14LMNA
SCHEMBL4408303 0.76 MAPK14 (0.43) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL4411116 0.75 MAPK14 (0.45) MAPK14MAPK13MAPK12MAPK11ADORA2A
SCHEMBL4409114 0.72 HTR3A (0.47) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL4410066 0.71 MAPK14 (0.47) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL4410189 0.70 MAPK14 (0.48) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL4411198 0.66 MAPK14 (0.51) MAPK14MAPK13MAPK12MAPK11GCGR
SCHEMBL6219431 0.66 HTR3A (0.63) MAPK14MAPK13MAPK12MAPK11GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2009-10-22 US claimed
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2008-12-25 US claimed
EP-1833828-A2 CONDENSED PYRIDINES AS KINASE INHIBITORS Palau Pharma, S.A. (ES) 2007-09-19 EP claimed
WO-2006013095-A2 CONDENSED PYRIDINES AS KINASE INHIBITORS PALAU PHARMA, S.A. (ES) 2006-02-09 WO claimed
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2009-10-22 US disclosed
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors PALAU PHARMA, S.A. (ES) 2008-12-25 US disclosed
EP-1833828-A2 CONDENSED PYRIDINES AS KINASE INHIBITORS Palau Pharma, S.A. (ES) 2007-09-19 EP disclosed
WO-2006013095-A2 CONDENSED PYRIDINES AS KINASE INHIBITORS PALAU PHARMA, S.A. (ES) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264446-A9 Condensed Pyridines as Kinase Inhibitors MAPK1, MAP4K2, MAP3K1 MAPK14 36/4885MAPK13 39/4885MAPK12 41/4885
US-20080318977-A1 Condensed Pyridines as Kinase Inhibitors MAPK1, MAP4K2, MAP3K1 MAPK14 36/4885MAPK13 39/4885MAPK12 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.